The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Share News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 8.00
Ask: 8.48
Change: -0.10 (-1.23%)
Spread: 0.48 (6.00%)
Open: 8.20
High: 8.20
Low: 8.00
Prev. Close: 8.10
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: K3 Capital upbeat; Morses sinks after warning

Tue, 21st Jun 2022 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

K3 Capital Group PLC, up 10% at 258.36 pence, 12-month range 205.00p-380.00p. The professional advisory services firm says its annual results are likely to exceed market expectations. K3 says for the year ended May 31, revenue is expected to grow by around 43% to GBP77.5 million, from GBP47.2 million the year before. Adjusted earnings before interest, tax, depreciation and amortisation are expected to be 24% higher at GBP19.5 million from GBP15.7 million. The figures exceed market expectations, which according to Numis sit at GBP63.5 million for revenue and GBP18.2 million in Ebitda.

----------

Oxford Biodynamics PLC, up 8.0% at 17.55p, 12-month range 15.50p-62.80p. Shares in biotech firm move off 12-month lows after its checkpoint inhibitor response test becomes available in the UK. The EpiSwitch CiRT blood test predicts a patient's likely response to immune checkpoint inhibitor therapies, with high levels of sensitivity, specificity, accuracy and negative predictive value across 15 cancer indications where ICI treatments are approved. The test is now available to private physicians in the UK online. Oxford says the appeal of the test for the UK's National Health Service, given the high rates of inefficacy of ICI treatments, and their high costs.

----------

Midatech Pharma PLC, up 7.8% at 9.43p, 12-month range 8.16p-38.00p. The biotechnology company receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.

----------

AIM - LOSERS

----------

Morses Club PLC, down 24% at 7.91p, 12-month range 4.50p-95.00p. The doorstep lender warns that an increase in complaints could badly affect its trading performance for the first half of its financial year. Morses says that its home collected credit division has seen a rise in complaints submitted by claims management firms, leading to claim volumes returning to the level seen in February. Should this level be sustained, Morses expects the cost of the complaints could hurt its trading performance for the six months ending August 31.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
16 Mar 2020 16:14

EXECUTIVE CHANGE SUMMARY: Globalworth Founder To Focus On Exec Role

EXECUTIVE CHANGE SUMMARY: Globalworth Founder To Focus On Exec Role

Read more
2 Mar 2020 19:43

CORRECT: Oxford BioDynamics Director Diggle Buys Shares

CORRECT: Oxford BioDynamics Director Diggle Buys Shares

Read more
26 Feb 2020 15:20

DIRECTOR DEALINGS: Oxford BioDynamics Director Diggle Buys Shares

DIRECTOR DEALINGS: Oxford BioDynamics Director Diggle Buys Shares

Read more
15 Jan 2020 15:17

Oxford BioDynamics Demonstrates Use Of EpiSwitch In Lymphoma Detection

Oxford BioDynamics Demonstrates Use Of EpiSwitch In Lymphoma Detection

Read more
23 Dec 2019 06:52

Oxford BioDynamics In Collaboration To Evaluate EpiSwitch Biomarkers

Oxford BioDynamics In Collaboration To Evaluate EpiSwitch Biomarkers

Read more
20 Dec 2019 10:43

UK WINNERS & LOSERS SUMMARY: Renewi Jumps 23% As Dutch Eco Ban Lifted

UK WINNERS & LOSERS SUMMARY: Renewi Jumps 23% As Dutch Eco Ban Lifted

Read more
11 Dec 2019 17:52

DIRECTOR DEALINGS: Oxford BioDynamics Director Diggle Buys Shares

DIRECTOR DEALINGS: Oxford BioDynamics Director Diggle Buys Shares

Read more
11 Dec 2019 16:11

Director dealings: Oxford Biodynamics interim chairman ups stake

(Sharecast News) - Oxford Biodynamics revealed on Wednesday that interim chairman Stephen Diggle had purchased 18,309 ordinary shares in the AIM-listed biotechnology firm.

Read more
10 Dec 2019 13:09

Oxford BioDynamics Annual Loss Widens On Increased Costs

Oxford BioDynamics Annual Loss Widens On Increased Costs

Read more
25 Oct 2019 11:58

Study Using Oxford BioDynamics' EpiSwitch Enrols First Patient

Study Using Oxford BioDynamics' EpiSwitch Enrols First Patient

Read more
28 Aug 2019 17:36

DIRECTOR DEALINGS: Oxford BioDynamics Director Diggle Buys Shares

(Alliance News) - Oxford BioDynamics PLC said that a company controlled by Non-Executive Director Stephen Diggle bought GBP36,000 worth of shares on Wednesday.Vulpes Life Sciences Fund, by

Read more
15 Aug 2019 15:36

DIRECTOR DEALINGS: Oxford BioDynamics Non-Executive Diggle Buys Shares

(Alliance News) - Oxford BioDynamics PLC on Thursday said Non-Executive Director Stephen Diggle acquired shares in the biotechnology company following a transaction on Wednesday.Diggle at a

Read more
6 Jun 2019 15:54

DIRECTOR DEALINGS: Non-Exec Linked Fund Buys Oxford BioDynamics Shares

LONDON (Alliance News) - Oxford BioDynamics PLC said Thursday that Vulpes Life Sciences Fund, controlled by Non-Executive Director Steven Diggle, purchased around GBP12,700 in shares in a on fund

Read more
31 May 2019 13:01

Long-Serving Oxford Biodynamics Non-Executive Kibble Stands Down

LONDON (Alliance News) - Biotechnology firm Oxford Biodynamics PLC said Friday Non-Executive Director Alison Kibble has stepped down from the firm after 11 years on the board.Kibble - first

Read more
28 May 2019 11:50

Oxford BioDynamics Half Year Loss Widens On Increased Costs

LONDON (Alliance News) - Oxford BioDynamics PLC on Tuesday said its loss widened in the first half of its financial year due to higher staff and administrative costs.Shares in Oxford were a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.